Altogether, rather than promoting weight loss, it was anticipated that GIP actions would promote weight gain and that a rational approach to obesity therapy therefore might be application of a GIP antagonist. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.